Trials / Withdrawn
WithdrawnNCT02241395
Cell Therapy as Treatment for Cerebral Palsy
Autologous Bone Marrow Mononuclear Cell Therapy in Cerebral Palsy
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Neurogen Brain and Spine Institute · Academic / Other
- Sex
- All
- Age
- 6 Months – 35 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to study the effect of autologous bone marrow mononuclear cells on common symptoms of cerebral palsy patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Intrathecal autologous bone marrow mononuclear cell transplantation |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2018-06-01
- Completion
- 2018-12-01
- First posted
- 2014-09-16
- Last updated
- 2018-10-25
Locations
1 site across 1 country: India
Source: ClinicalTrials.gov record NCT02241395. Inclusion in this directory is not an endorsement.